|
New collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines
|
02 September 2020 |
|
Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19
|
17 July 2020 |
|
Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US
|
02 July 2020 |
|
Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges
|
24 June 2020 |
|
Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts
|
22 June 2020 |
|
Novartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia
|
28 April 2020 |
|
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program
|
07 April 2020 |
|
Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human Services
|
31 March 2020 |
|
Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation
|
27 March 2020 |
|
Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response
|
23 March 2020 |